Simplify Logo

Full-Time

Senior Manager

Financial Reporting and Technical Accounting

Posted on 8/12/2024

Korro Bio

Korro Bio

51-200 employees

Develops RNA-based therapies for diseases

Biotechnology
Healthcare

Mid, Senior

Cambridge, MA, USA

Onsite position at One Kendall Square, Building 600, Cambridge, MA 02139.

Category
Financial Accounting
Accounting
Required Skills
NetSuite
Requirements
  • Bachelor's degree in Accounting from an accredited university
  • CPA and public accounting experience required (Big 4 preferred)
  • 4-6 years' accounting experience, with at least 2 years' SEC reporting
  • Strong knowledge of US GAAP, SEC reporting requirements and SOX 404, as well as experience with technical research
  • Exposure to consolidation and a multi-currency environment
  • Biotech or life sciences industry experience strongly preferred
  • Ability to work closely with management
  • Commitment to all reporting and audit deadlines
  • Strong Excel skills and MS Office Suite
  • Experience with NetSuite ERP software and Fidelity Equity platform
  • Ability to function at a high level in a team setting whether leading or as an individual contributor
  • Excellent communication skills, written, verbal and interpersonal skills
  • Sound judgment and critical thinking skills
  • Highly detail oriented and meticulous with data
  • Ability to handle multiple tasks and shift with changing priorities
  • Very organized with effective time management and ability to meet tight deadlines
  • Independent problem solver, comfortable in small company environments where taking on various responsibilities is inevitable
Responsibilities
  • Prepare SEC reporting documents (10-Q, 10-K, Proxy, 8-K). Prepare quarterly cash flow statement, earnings per share and equity roll forward workbooks.
  • Prepare footnote support schedules, tie-out binders for SEC filings and disclosure checklists.
  • Assist with research and preparation of technical accounting memos.
  • Collaborate with the general accounting team to prepare corporate financial reporting for internal analysis and external SEC filings.
  • Collaborate with the legal team to ensure compliance with SEC regulations.
  • Preparation of quarterly R&D accruals including pre-clinical accruals, clinical accruals and CDMO accruals.
  • Preparation of quarterly stock-based compensation expense calculation and related analytical support files.
  • Work closely with external auditors to manage the financial quarterly review and annual audit process.
  • Ensure internal controls over financial reporting, including disclosure controls and procedures, are adequate and operating effectively.
  • Maintain/update process flows and internal controls over financial reporting (Sarbanes-Oxley "SOX" Compliance).
  • Provide support to internal and external auditors during financial and SOX audits and interim reviews.
  • Participate in monthly/quarterly financial close review meetings to ensure appropriate accounting of transactions and accurate external reporting.
  • Participate in special projects and ad hoc requests as needed.

Korro Bio develops RNA-based therapies aimed at treating serious diseases that lack effective treatments. The company uses RNA editing to make precise modifications at the RNA level, which allows for accurate changes in protein function. This method is seen as more precise and potentially safer than traditional gene editing techniques. Korro Bio focuses on research and development to create new therapies, which it can market independently or through partnerships with larger pharmaceutical companies. The company serves healthcare providers, hospitals, and patients, and collaborates with academic institutions to enhance its research. Korro Bio's goal is to advance RNA editing technology to provide new treatment options for patients suffering from debilitating diseases.

Company Stage

IPO

Total Funding

$451.5M

Headquarters

Cambridge, Massachusetts

Founded

2019

Growth & Insights
Headcount

6 month growth

3%

1 year growth

1%

2 year growth

30%
Simplify Jobs

Simplify's Take

What believers are saying

  • The $70 million raised for clinical trials and growth positions Korro Bio to advance its pipeline and achieve significant milestones.
  • The appointment of industry veterans like Dr. Rachel Meyers and Tim Pearson to the board strengthens the company's leadership and strategic direction.
  • Korro Bio's stock price surge of 171% in November indicates strong market confidence and potential for high returns.

What critics are saying

  • The biopharmaceutical market is highly competitive, and Korro Bio must continuously innovate to maintain its edge.
  • The success of RNA editing therapies is still uncertain and hinges on successful clinical trials and regulatory approvals.

What makes Korro Bio unique

  • Korro Bio's focus on RNA editing allows for precise single base modifications, offering a potentially safer and more accurate alternative to traditional gene editing and gene therapy.
  • The company's strategy of leveraging machine learning to enhance RNA delivery and platform development sets it apart from competitors.
  • Korro Bio's recent $70 million private placement and merger with Frequency Therapeutics provide substantial financial backing and expanded capabilities.
INACTIVE